Print

ANDA Litigation Settlements

Case Name Drug Patent No(s). Publicly Available Terms
Vivus Inc. v. Actavis Labs. FL Inc., 14-3786 (D.N.J.) Qsymia® (phentermine / topiramate) 7,056,890
7,553,818
7,659,256
7,674,776
8,580,298
8,580,299
Actavis to start selling its generic product on Dec. 1, 2024, or earlier “under certain circumstances.” Should Actavis begin selling a generic before its 2024 deadline, Vivus will collect royalties.
Eli Lilly and Co. v. Actavis Labs. UT Inc., 16-1119 (E.D. Va.) Cialis® (tadalafil tablets) 6,943,166 Eli Lilly retains exclusivity over Cialis market until at least Sept. 27, 2018. Eli Lilly and generic defendants entered into a royalty-bearing license agreement.  
Purdue Pharma L.P. v. Mylan Pharms. Inc., 15-1155 (D. Del.) OxyContin® (oxycodone HCl extended-release tablets) 9,073,933 N/A
Amgen v. Apotex Inc., 16-0926 (D. Del.) Sensipar® (cinacalcet tablets) 9,375,405 N/A
Amgen Inc. v. Micro Labs Ltd., 16-0854 (D. Del.) Sensipar® (cinacalcet tablets) 9,375,405 N/A
AstraZeneca Pharms. LP v. Amneal Pharms. LLC, 15-1139 (D. Del.) Byetta® (exenatide for injection) 6,872,700
6,902,744
N/A
AstraZeneca AB v. Torrent Pharma Inc., 15-3375 (D.N.J.) Daliresp® (roflumilast tablets) 5,712,298
8,536,206
8,604,064
8,618,142
N/A

The articles on our Website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice.